Ocugen (OCGN) said Monday that two-year data from a phase 1/2 trial showed that OCU400 improved visual function in children and adults with retinitis pigmentosa.
The company said treatment with the drug candidate showed "meaningful" improvement of 2-line gain, or 10 letters on ETDRS chart, in low-luminance visual acuity.
The effect of the treatment was "statistically significant" in all subjects regardless of mutation at two years, the company added.
Ocugen said it is conducting a phase 3 trial and expects to submit a biologics license application in H1 2026 as planned.
The company's shares were falling 4.4% in recent trading.
Price: 0.75, Change: -0.03, Percent Change: -4.39
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。